|
Oct 23
|
Recent 4.1% pullback isn't enough to hurt long-term Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders, they're still up 70% over 1 year
|
|
Sep 26
|
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
|
|
Aug 29
|
Ultragenyx to Participate in Investor Conferences in September
|
|
Jul 25
|
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
|
|
Jul 24
|
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
|
|
Jul 22
|
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
|
|
Jul 18
|
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
|
|
Jul 17
|
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
|
|
Jun 14
|
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
|
|
Jun 13
|
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
|
|
Jun 13
|
Increases to CEO Compensation Might Be Put On Hold For Now at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
|
|
Jun 13
|
Insider Sale: EVP and Chief Legal Officer Karah Parschauer Sells Shares of Ultragenyx ...
|
|
Jun 12
|
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
|
|
Jun 12
|
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
|
|
Jun 12
|
Ultragenyx (RARE) Posts New Data From Bone Disease Study
|
|
May 22
|
Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells
|
|
May 7
|
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
|
|
May 4
|
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript
|
|
May 4
|
Here's What Analysts Are Forecasting For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter Results
|
|
May 3
|
Ultragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ...
|